| Literature DB >> 21887294 |
Chung-Ta Chang1, Ho Lin, Tin-Yun Ho, Chia-Cheng Li, Hsin-Yi Lo, Shih-Lu Wu, Yi-Fang Huang, Ji-An Liang, Chien-Yun Hsiang.
Abstract
The aim of this study was to analyze the host responses to ionizing radiation by nuclear factor-κB (NF-κB) bioluminescence imaging-guided transcriptomic tool. Transgenic mice carrying the NF-κB-driven luciferase gene were exposed to a single dose of 8.5 Gy total-body irradiation. In vivo imaging showed that a maximal NF-κB-dependent bioluminescent intensity was observed at 3 h after irradiation and ex vivo imaging showed that liver, intestine, and brain displayed strong NF-κB activations. Microarray analysis of these organs showed that irradiation altered gene expression signatures in an organ-specific manner and several pathways associated with metabolism and immune system were significantly altered. Additionally, the upregulation of fatty acid binding protein 4, serum amyloid A2, and serum amyloid A3 genes, which participate in both inflammation and lipid metabolism, suggested that irradiation might affect the cross pathways of metabolism and inflammation. Moreover, the alteration of chemokine (CC-motif) ligand 5, chemokine (CC-motif) ligand 20, and Jagged 1 genes, which are involved in the inflammation and enterocyte proliferation, suggested that these genes might be involved in the radiation enteropathy. In conclusion, this report describes the comprehensive evaluation of host responses to ionizing radiation. Our findings provide the fundamental information about the in vivo NF-κB activity and transcriptomic pattern after irradiation. Moreover, novel targets involved in radiation injury are also suggested.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21887294 PMCID: PMC3161058 DOI: 10.1371/journal.pone.0023682
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1NF-κB-dependent bioluminescence in living mice.
Transgenic mice were exposed to ionizing radiation and imaged in ventral (A) and dorsal positions (B) at indicated periods. In vivo imaging was shown on the left panel. The color overlay on the image represents the photons/sec emitted from the animal, as indicated by the color scale. Photos are representative images (n = 10). Quantification of photon emission from the whole animal was shown on the right panel. Shown is the total photon flux plotted over time. Values are mean ± standard error (n = 10). * p<0.05, ** p<0.01, compared with mock.
Figure 2NF-κB-dependent bioluminescence in individual organs.
Transgenic mice were exposed to ionizing radiation. Three hours later, mice were sacrificed and organs were subjected to image. (A) Ex vivo imaging. The color overlay on the image represents the photons/sec emitted from the organ, as indicated by the color scale. Photos are representative images (n = 10). (B) Quantification of photon emission from the organ. Values are mean ± standard error (n = 10). * p<0.05, ** p<0.01, *** p<0.001, compared with mock.
Figure 3Histological examination, immunohistochemical staining, and immunofluorescence staining of organs exposed to ionizing radiation.
(A) Histological examination and immunohistochemical staining. Transgenic mice were exposed to irradiation. Three hours later, mice were sacrificed, organs were excised, and the sections were stained with H&E or by immunohistochemistry using antibody against NF-κB (400× magnification). Photos are representative images (n = 6). (B) Immunofluorescence staining. Sections from irradiation-exposed organs were stained with antibodies against NF-κB (green) , olig2 (ref), F4/80 (ref), or PLA2 (ref). Overlap of markers appears as yellow color in the right panels. Scale bars = 10 µm. Photos are representative images (n = 3).
KEGG pathway analysis of genes in organs at 3 h after ionizing radiation.
| KEGG pathway |
| ||
| Intestine | Brain | Liver | |
|
| |||
| Arginine and proline metabolism | 0.01130 (52/0/2) | 0.00338 (52/3/1) | 0.02077 (52/1/2) |
| Bile acid biosynthesis | 2.9×10−6 (34/3/2) | 0.68843 (34/0/0) | 0.01253 (34/4/3) |
| Butanoate metabolism | 0.00250 (41/1/3) | 0.14750 (41/1/0) | 0.00391 (41/4/6) |
| Citrate cycle (TCA cycle) | 0.00078 (24/1/3) | 0.01938 (24/0/0) | 0.00043 (24/1/1) |
| Fatty acid metabolism | 0.00003 (36/4/3) | 0.23500 (36/0/0) | 0.14559 (36/3/1) |
| Glycerolipid metabolism | 6.0×10−6 (38/2/4) | 0.01790 (38/3/1) | 0.03965 (38/3/6) |
| Glycerophospholipid metabolism | 0.42737 (51/0/0) | 0.13926 (51/0/0) | 0.02609 (51/2/5) |
| Linoleic acid metabolism | 0.00998 (40/1/2) | 0.99948 (40/0/1) | 0.00071 (40/4/3) |
| Lysine degradation | 0.68298 (69/1/0) | 0.00378 (69/10/1) | 0.04571 (69/5/6) |
| Metabolism of xenobiotics by cytochrome p450 | 1.5×10−7 (52/2/6) | 0.61449 (52/0/2) | 0.00068 (52/3/6) |
| N-Glycan biosynthesis | 0.00628 (32/0/1) | 0.08642 (32/1/0) | 0.25735 (32/0/1) |
| Oxidative phosphorylation | 7.7×10−13 (101/2/13) | 3.6×10−16 (101/4/15) | 5.2×10−8 (101/3/4) |
| Pyruvate metabolism | 0.00003 (31/3/0) | 0.00632 (31/2/2) | 0.00935 (31/3/3) |
| Tryptophan metabolism | 0.02084 (59/4/2) | 0.06264 (59/1/1) | 0.03921 (59/3/5) |
| Valine, leucine and isoleucine degradation | 0.01356 (41/3/1) | 0.26859 (41/0/0) | 0.00305 (41/2/5) |
|
| |||
| B cell receptor signaling pathway | 0.01122 (64/3/1) | 0.00713 (64/4/0) | 0.43761 (64/0/0) |
| Complement and coagulation cascades | 0.09729 (68/0/3) | 0.57659 (68/0/1) | 0.02019 (68/4/2) |
| Hematopoietic cell lineage | 0.00553 (82/4/2) | 0.15968 (82/2/0) | 0.48065 (82/6/2) |
|
| |||
| Apoptosis | 0.01736 (80/6/1) | 0.03479 (80/5/2) | 0.73307 (80/0/0) |
| Gap junction | 0.16539 (81/1/0) | 0.00005 (81/9/2) | 0.11232 (81/4/3) |
| Regulation of actin cytoskeleton | 0.00419 (193/2/4) | 7.3×10−6 (193/12/7) | 0.08328 (193/9/9) |
|
| |||
| Insulin signaling pathway | 0.05099 (77/1/0) | 0.00004 (77/14/0) | 0.01390 (77/2/10) |
| MAPK signaling pathway | 0.01767 (248/5/5) | 0.00006 (248/13/12) | 0.33913 (248/3/6) |
| PPAR signaling pathway | 0.00409 (70/5/1) | 0.17488 (70/2/0) | 0.00117 (70/5/5) |
|
| |||
| Proteasome | 0.000547 (30/0/3) | 0.01046 (30/1/2) | 0.00001 (30/4/2) |
| Ribosome | 4.7×10−18 (80/2/17) | 6.7×10−17 (80/0/24) | 2.4×10−6 (80/13/2) |
Genes with fold changes >1.8 or <−1.8 were analyzed by KEGG pathways.
p values were calculated by the geneSetTest function implemented in the limma package.
Total number of genes in this pathway / Number of upregulated genes in this pathway/Number of downregulated genes in this pathway.
Figure 4GO analysis of organs after irradiation.
Differential expressed genes responsive to ionizing radiation were organized using Gene Ontology Tree Machine. The significantly regulated GO categories in brain, liver, and intestine are indicated.
The expression levels of genes belonging to the GO categories of “immune system process” and “response to stress”.
| Gene description | Fold changes | ||
| Intestine | Brain | Liver | |
|
| |||
| Heat shock protein 1 (chaperonin) | −5.63±1.20 | 1.22±0.03 | −1.43±0.35 |
| Heat shock protein 8 | −1.17±0.91 | −1.20±0.75 | −2.80±1.50 |
|
| |||
| CD79B antigen | −5.80±1.13 | 1.15±0.07 | 1.15±0.07 |
| CD 81 antigen | 3.00±0.35 | 1.40±0.28 | 1.50±0.57 |
| Chemokine (CC motif) ligand 5 | −2.50±0.70 | −0.55±0.64 | −1.15±0.07 |
| Chemokine (CC motif) ligand 19 | −1.90±0.14 | 1.10±0.03 | −1.30±0.28 |
| Chemokine (CC motif) ligand 20 | −2.85±0.21 | 0.37±1.18 | 1.13±0.06 |
| Chemokine (CXC motif) ligand 1 | 1.85±0.49 | 1.15±0.07 | 7.05±2.62 |
| Chemokine (CXC motif) ligand 9 | 1.85±0.49 | −1.23±0.23 | −1.53±0.45 |
| Chemokine (CXC motif) ligand 12 | −2.17±0.21 | 1.15±0.21 | −1.10±0.10 |
| Chemokine (CXC motif) ligand 16 | 1.30±0.82 | 1.40±0.85 | 1.93±0.78 |
| Conserved helix-loop-helix ubiquitous kinase | −2.17±0.06 | 1.10±0.14 | −1.25±0.21 |
| Cysteine-rich protein 3 | 1.65±0.78 | −0.80±0.35 | −1.55±0.64 |
| Interleukin 22 | −0.60±2.26 | −3.50±0.57 | 1.30±0.20 |
| Jagged 1 | 2.40±0.28 | 1.07±0.06 | 1.13±0.15 |
| Kinase insert domain protein receptor | 2.25±0.07 | 1.13±0.15 | −1.33±0.25 |
| S100 calcium binding protein A9 (calgranulin B) | 1.83±0.29 | 1.30±0.04 | 1.80±0.60 |
| Signal transducer and activator of transcription 3 | 2.40±0.53 | 1.42±0.49 | −1.43±0.35 |
| Tumor necrosis factor receptor superfamily, member 13c | −2.03±0.06 | 1.03±0.06 | 1.13±0.06 |
|
| |||
| C-reactive protein, pentraxin-related | 2.30±0.87 | −2.50±1.85 | 1.40±0.20 |
| Complement component 1, q subcomponent, alpha polypeptide | 1.87±1.21 | −1.60±0.50 | −1.20±0.10 |
| Fibrinogen, gamma polypeptide | −3.13±1.10 | −1.05±0.07 | 2.60±1.27 |
| Hemolytic complement | −2.20±1.13 | 1.13±0.06 | −1.70±0.28 |
| Serine (or cysteine) peptidase inhibitor, clade A, member 1a | −2.73±0.81 | −1.23±0.15 | −1.17±0.15 |
| Serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1 | −3.70±1.57 | 1.10±0.14 | −1.73±0.45 |
| Serum amyloid A 2 | −2.20±0.60 | 1.20±0.28 | 13.37±5.35 |
| Serum amyloid A 3 | 2.47±0.64 | 1.30±0.28 | 11.65±5.02 |
|
| |||
| Alpha 1 microglobulin/bikunin | −3.13±1.01 | −1.30±0.28 | −1.28±0.03 |
| B-cell translocation gene 2, anti-proliferative | 2.77±0.74 | 1.25±0.21 | 1.27±0.25 |
| Bcl2-associated X protein | 3.87±1.40 | 1.25±0.21 | 1.53±0.15 |
| Caspase 8 | −2.73±0.76 | −1.03±0.04 | −1.35±0.35 |
| Cyclin-dependent kinase inhibitor 1A (P21) | 2.80±0.69 | 1.60±0.40 | 1.40±0.42 |
| Gap junction membrane channel protein alpha 1 | −0.70±2.97 | −2.75±0.35 | 1.08±0.04 |
| Growth arrest and DNA-damage-inducible 45 alpha | −6.10±3.42 | 1.11±0.01 | −2.08±0.04 |
| Guanylate nucleotide binding protein 1 | 2.20±0.60 | 1.30±0.20 | −1.65±0.78 |
| Mitogen activated protein kinase 1 | −2.80±0.72 | 0.40±2.10 | −1.15±0.21 |
| Mitogen activated protein kinase 3 | −1.87±0.76 | −1.23±0.15 | −2.20±0.10 |
| Nucleophosmin 1 | −2.90±1.35 | −1.30±0.28 | 1.60±0.28 |
| Trefoil factor 1 | −2.27±0.61 | −1.20±0.10 | −1.55±0.78 |
|
| |||
| Early growth response 1 | −1.23±1.00 | −1.10±0.53 | −2.20±1.27 |
| Interferon regulatory factor 7 | 1.40±1.20 | −3.30±1.00 | 1.08±0.04 |
|
| |||
| Adenosine deaminase | −2.93±0.76 | 1.20±0.28 | 1.05±0.07 |
| Apolipoprotein E | −1.80±0.53 | −1.77±0.45 | −1.30±0.28 |
| Fatty acid binding protein 4, adipocyte | 1.23±0.80 | 1.00±0.03 | 3.37±2.35 |
| Ferritin heavy chain 1 | −2.67±1.10 | −2.17±0.85 | 1.67±0.25 |
| Glutathione peroxidase 1 | −3.07±0.83 | −2.10±0.40 | −1.40±0.14 |
Values are mean ± standard error (n = 6).
Expression levels of Ccl5, Ccl20, Jagged1, SAA2, and SAA3 genes by qPCR.
| Sample | Average CT of target | Average CT of GAPDH | ΔCT
| ΔΔCT
| Relative to Mock |
|
| |||||
| Ccl5 | |||||
| Mock | 26.88±0.11 | 20.03±0.10 | 6.85±0.15 | 0.00±0.15 | 1.00 |
| Ionizing radiation | 26.19±0.04 | 19.02±0.02 | 7.17±0.05 | 0.31±0.05 | 0.80 |
| Ccl20 | |||||
| Mock | 22.36±0.04 | 19.73±0.01 | 2.62±0.05 | 0.00±0.05 | 1.00 |
| Ionizing radiation | 22.92±0.03 | 19.92±0.03 | 2.99±0.05 | 0.36±0.05 | 0.77 |
| Jagged1 | |||||
| Mock | 27.13±0.02 | 19.73±0.01 | 7.40±0.03 | 0.00±0.03 | 1.00 |
| Ionizing radiation | 26.80±0.10 | 19.92±0.03 | 6.88±0.10 | −0.52±0.10 | 1.43 |
|
| |||||
| SAA2 | |||||
| Mock | 27.81±0.10 | 18.41±0.03 | 9.40±0.11 | 0.00±0.11 | 1.00 |
| Ionizing radiation | 24.49±0.10 | 18.64±0.04 | 5.85±0.11 | −3.55±0.11 | 11.71 |
| SAA3 | |||||
| Mock | 27.66±0.11 | 19.73±0.01 | 7.93±0.11 | 0.00±0.11 | 1.00 |
| Ionizing radiation | 26.82±0.08 | 19.92±0.03 | 6.90±0.09 | −1.03±0.09 | 2.04 |
The ΔCT value is determined by subtracting the average GAPDH CT value from the average target gene CT value. The standard deviation of the difference is calculated from the standard deviations of the target gene and GAPDH.
The calculation of ΔΔCT involves subtraction by the ΔCT calibrator value. This is a subtraction of an arbitrary constant, so the standard deviation of ΔΔCT is the same as the standard deviation of the ΔCT value.